Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia

Pseudomonas aeruginosa is amongst the most common causes of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) worldwide [1]. Since the past decade, P. aeruginosa has become resistant to the commonly-used antipseudomonal agents, including carbapenems with an incidence of 7-44% depending on geographical regions [2]. The emergence of extensively drug-resistant P. aeruginosa (XDR-PA) pneumonia is increasingly recognized as a major threat to patients and healthcare systems given its associated morbidity, mortality and healthcare costs [3,4].

Source: International Journal of Antimicrobial Agents - September 17, 2018 Category: Drugs & Pharmacology Authors: Thana Khawcharoenporn, Alan Chuncharunee, Chailat Maluangnon, Thitiporn Taweesakulvashra, Pimsiri Tiamsak Source Type: research